GILEAD SCIENCES, INC. (NASDAQ:GILD) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition.
|
(Gilead), issued a press release announcing its financial results
for the quarter ended March 31, 2017. A copy of the press release
is filed as Exhibit 99.1 to this report.
with U.S. generally accepted accounting principles (GAAP) and also
on a non-GAAP basis for the three months ended March 31,
2017>and 2016. Management believes this non-GAAP information is
useful for investors, when considered in conjunction with Gilead’s
GAAP financial statements, because management uses such information
internally for its operating, budgeting and financial planning
purposes. Non-GAAP information is not prepared under a
comprehensive set of accounting rules and should only be used to
supplement an understanding of Gileads operating results as
reported under GAAP. Non-GAAP measures may be defined and
calculated differently by other companies in the same industry. A
reconciliation between GAAP and non-GAAP financial information is
provided in the tables on pages 7, 8 and 9 of the press release
filed as Exhibit 99.1 to this report.
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act), or
otherwise subject to the liabilities under that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, regardless
of any general incorporation language in such filing.
|
Exhibit Number
|
|
Description
|
|
99.1
|
|
Press Release, issued by Gilead Sciences, Inc. on May 2,
2017 |
About GILEAD SCIENCES, INC. (NASDAQ:GILD)
Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company’s liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company’s cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company’s Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases. GILEAD SCIENCES, INC. (NASDAQ:GILD) Recent Trading Information
GILEAD SCIENCES, INC. (NASDAQ:GILD) closed its last trading session up +0.48 at 68.59 with 5,372,585 shares trading hands.
